Register to gain access to personalised information regarding Brand, the indications your are treating regularly, dosing guidelines and resources such as Major Studies, Patient Information and short videos curated to your special interest.

Consistent Protection after Hip Replacement Surgery, Evidenced in Clinical Studies,1,2 Reaffirmed in the Real-World3

Prevention of VTE after elective hip replacement surgery

The first approved indication4 for Xarelto^® was for the prevention of venous thromboembolism in adults undergoing elective hip replacement surgery

Superior Protection for Your Elective Hip Surgery Patients1

Provide better protection against DVT , nonfatal PE and death from any cause vs enoxaparin

Xarelto significantly reduces DVT (either symptomatic or detected by bilateral venography if the patient was asymptomatic), nonfatal PE , or death from any cause by 2.6% ARR vs enoxaparin.1

Comparable Safety Profile1

Maintain a low major bleeding rate vs enoxaparin

Treatment with Xarelto results in a similar major bleeding rate as enoxaparin in elective hip replacement surgery patients.1

Effective Extended Thromboprophylaxis2

Better protect your patients for longer vs enoxaparin

Extended treatment with Xarelto 10 mg OD for up to 39 days significantly reduces DVT (either symptomatic or detected by bilateral venography if the patient was asymptomatic), nonfatal PE , or death from any cause by 7.3% ARR vs up to 14 days of enoxaparin 40 mg OD.2

Consistent Protection Confirmed in the Real World3

Give your everyday patients the consistent protection they need

Xarelto has been associated with significantly lower symptomatic thromboembolic events vs standard of care (0.9% vs 1.4% [OR, 0.65; 95% CI, 0.49–0.87]) in elective hip and knee surgery patients3

* Standard of care included, but was not limited to, LMWHs, unfractionated heparins, fondaparinux, dabigatran etexilate, acetylsalicylic acid and vitamin K antagonists.

Major bleeding rates were similar in patients treated with either Xarelto or standard of care.3

* Standard of care included, but was not limited to, LMWHs, unfractionated heparins, fondaparinux, dabigatran etexilate, acetylsalicylic acid and vitamin K antagonists.
^†As defined in the RECORD studies clinically overt bleeding that was fatal, occurred in a critical organ, necessitated re-operation or was outside of the surgical site and was associated with a fall in haemoglobin of ≥2 g/dl or required a transfusion of ≥2 units of blood.

ARR, absolute risk reduction; CI, confidence interval; DVT , deep vein thrombosis ; ITT , intention-to-treat; LMWH , low-molecular-weight heparin; OD, once daily; OR, odds ratio; PE , pulmonary embolism; RRR , relative risk reduction; VTE , venous thromboembolism.

PP-XAR-ALL-1793-1

References

Eriksson BI, et al. N Engl J Med. 2008;358:2765–2775. Eriksson BI, et al. N Engl J Med. 2008;358:2765–2775. Return to content
Kakkar AK, et al. Lancet. 2008:372(9632):31–9. Kakkar AK, et al. Lancet. 2008:372(9632):31–9. Return to content
Turpie AG, et al. Thromb Haemost. 2014;111:94–102. Return to content
Xarelto (rivaroxaban) Summary of Product Characteristics. Xarelto (rivaroxaban) Summary of Product Characteristics. Return to content

RELATED PODCAST
CAD or symptomatic PAD discussion

RELATED VIDEOS
Coronary Artery Disease Causes and Consequences

DOSING GUIDE

PRACTICAL MANAGEMENT

PRESCRIBING INFORMATION

Consistent Protection after Hip Replacement Surgery, Evidenced in Clinical Studies,1,2 Reaffirmed in the Real-World3

Prevention of VTE after elective hip replacement surgery